Human papillomavirus vaccine legislation in Kentucky: a policy analysis.
The purpose of this article is to discuss the problem of cervical cancer, examine policy solutions, and analyze factors that contributed to the failure of human papillomavirus (HPV) vaccine requirement legislation in Kentucky. During 2007, a Kentucky representative introduced legislation that would require HPV vaccination for all middle-school girls but allow parents to opt out for any reason. Evidence suggests that an HPV school requirement law would result in more Kentucky children being vaccinated than if there were no requirement law. However, this policy solution faced multiple factors that inhibited its ability to survive. Future proponents of HPV vaccine school requirement legislation can draw implications from Kentucky's experience. By building public support, undergoing a softening up period, and presenting a united, vocal front, proponents may be more likely to pass HPV vaccine legislation in the future.
Dekker
Rebecca L
RL
University of Kentucky College of Nursing, Lexington, KY 40536-0232 USA. rdekker@uky.edu
D002423:Cause of Death; D002487:Centers for Disease Control and Prevention, U.S.; D002648:Child; D002669:Child Welfare / Q000331:legislation & jurisprudence; D019317:Evidence-Based Medicine; D005260:Female; D006291:Health Policy / Q000331:legislation & jurisprudence*; D006301:Health Services Needs and Demand; D054624:Health Status Disparities; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D007115:Immunization Schedule; D015994:Incidence; D007629:Kentucky / Q000453:epidemiology; D037141:Mandatory Programs / Q000191:economics / Q000331:legislation & jurisprudence*; D053918:Papillomavirus Vaccines / Q000191:economics / Q000600:supply & distribution; D010342:Patient Acceptance of Health Care; D011050:Policy Making; D011057:Politics; D012574:Schools / Q000331:legislation & jurisprudence; D012959:Socioeconomic Factors; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000517:prevention & control*; D014611:Vaccination / Q000191:economics / Q000331:legislation & jurisprudence*
D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines